Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$0.97 USD

0.97
1,242,660

+0.02 (2.20%)

Updated May 31, 2024 04:00 PM ET

After-Market: $0.98 +0.01 (1.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

7 items in cart

View Cart/Checkout

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 341 - 360 ( 386 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 341

09/08/2016

Company Report

Pages: 3

Positive Selinexor Data in Penta Myeloma Population; Ratcheting PT to $16 from $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 342

09/06/2016

Company Report

Pages: 6

Selinexor Shows Meaningful Activity in STORM, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 343

08/26/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of August 29

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 344

08/19/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 345

08/18/2016

Company Report

Pages: 15

Initiating Coverage With a Buy Ahead of a Slew of Selinexor Readouts

Provider: H.C. Wainwright & Co., Inc.

Analyst: DEEPAK S

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 346

08/18/2016

Industry Report

Pages: 18

HEALTHCARE - 2016 PacGrow Healthcare Conference Day 2

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 347

08/04/2016

Company Report

Pages: 8

2Q Results, Major Data Catalysts Up Ahead, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 348

07/29/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of August 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 349

07/15/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 350

06/10/2016

Company Report

Pages: 6

Selinexor shows Good Responses and Resensitizes Refractory MM Tumors, Reiterate OP but reducing PT to $14 on Intensifying Competitive Landscape

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 351

06/03/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 352

05/19/2016

Industry Report

Pages: 8

ASCO 2016 Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 353

05/09/2016

Company Report

Pages: 7

1Q, Multiple Catalysts in Place for 2016, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 354

05/06/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 355

04/21/2016

Industry Report

Pages: 8

Biotechnology AACR Roundup for Covered Companies.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 356

03/15/2016

Company Report

Pages: 10

4Q; Despite Setbacks in Timeline, Selinexor Program Remains on Track, Reiterate OP but Reducing PT to $16

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 357

03/11/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 358

12/11/2015

Industry Report

Pages: 6

Biotechnology/Biopharmaceuticals - ASH Recap 2015

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 359

12/08/2015

Company Report

Pages: 7

Impressive Selinexor Combo Data at ASH, Trimming our PT on DLBCL Delay, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 360

12/04/2015

Industry Report

Pages: 5

Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party